Fmr LLC Boosts Position in Masimo Co. (MASI)

Fmr LLC boosted its holdings in Masimo Co. (NASDAQ:MASI) by 6,605.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,821,994 shares of the medical equipment provider’s stock after purchasing an additional 1,794,822 shares during the quarter. Fmr LLC’s holdings in Masimo were worth $177,918,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of MASI. Segall Bryant & Hamill LLC acquired a new stake in Masimo in the second quarter valued at approximately $1,280,000. BancorpSouth Bank acquired a new stake in Masimo in the second quarter valued at approximately $212,000. Redwood Investments LLC grew its position in Masimo by 26.7% in the second quarter. Redwood Investments LLC now owns 265,812 shares of the medical equipment provider’s stock valued at $25,957,000 after acquiring an additional 56,005 shares in the last quarter. First Trust Advisors LP grew its position in Masimo by 215.9% in the second quarter. First Trust Advisors LP now owns 11,206 shares of the medical equipment provider’s stock valued at $1,094,000 after acquiring an additional 7,659 shares in the last quarter. Finally, Kaizen Advisory LLC grew its position in Masimo by 298.6% in the second quarter. Kaizen Advisory LLC now owns 12,795 shares of the medical equipment provider’s stock valued at $1,249,000 after acquiring an additional 9,585 shares in the last quarter. Hedge funds and other institutional investors own 82.88% of the company’s stock.

In other news, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $110.00, for a total transaction of $1,100,000.00. Following the completion of the sale, the director now owns 74,832 shares of the company’s stock, valued at $8,231,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Joe E. Kiani sold 239,926 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $117.95, for a total transaction of $28,299,271.70. Following the sale, the chief executive officer now directly owns 236,061 shares of the company’s stock, valued at approximately $27,843,394.95. The disclosure for this sale can be found here. Insiders have sold 736,107 shares of company stock valued at $87,551,638 in the last three months. Corporate insiders own 12.60% of the company’s stock.

MASI stock opened at $111.35 on Friday. Masimo Co. has a twelve month low of $80.69 and a twelve month high of $126.89. The company has a market cap of $5.90 billion, a PE ratio of 45.45, a P/E/G ratio of 2.58 and a beta of 1.11.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.02. Masimo had a net margin of 17.08% and a return on equity of 20.29%. The business had revenue of $210.58 million during the quarter, compared to the consensus estimate of $207.62 million. During the same quarter last year, the company earned $0.56 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. Research analysts expect that Masimo Co. will post 2.92 EPS for the current fiscal year.

Several analysts have issued reports on the stock. BidaskClub downgraded shares of Masimo from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Piper Jaffray Companies increased their price objective on shares of Masimo to $120.00 and gave the company a “neutral” rating in a research report on Thursday. Stifel Nicolaus increased their price objective on shares of Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Needham & Company LLC assumed coverage on shares of Masimo in a research report on Friday, September 14th. They issued a “buy” rating for the company. Finally, Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Masimo has an average rating of “Buy” and a consensus price target of $114.40.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Read More: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply